AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. HOOD
10. RGNX

Go back to AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

Jefferies Reiterates Buy Rating on Amgen (AMGN) as Lumakras Phase III CB200 Hits

August 31, 2022 8:29 AM EDT

Jefferies analyst Michael Yee reiterated a Buy rating and $295.00 price target on Amgen (NASDAQ: AMGN) after Lumakras Phase III CB200 hits, which he said is "good enough."

The analyst commented, "AMGN announced the Lumakras Phase III CB-200 study was positive although mostly... More